Inpharmica Overview
- Founded
-
2015
- Status
-
Private
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$356K
- Investors
-
1
Inpharmica General Information
Description
Developer of a bio-medicine technology designed to aid complex painkiller drug development. The company's technology is used in performing phase III of clinical studies on an increased number of patients, including the monitoring of undesired effects and the development of documentation to register a new complex painkiller patented, enabling patients to access next-generation pain-killers.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- Ul. Czerwonych Maków 12 lok. 13
- Warsaw, Mazowieckie
- Poland
+48 600 000 000
Inpharmica Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 18-Dec-2015 | $356K | 00000 | Completed | Generating Revenue |
Inpharmica Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Dorota Święcicka | Executive |
Inpharmica Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Szczepan Adamski | Inpharmica | Chairman | 000 0000 |
| Weronika Kiełczewska | Inpharmica | Board Member | 000 0000 |
Inpharmica Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Black Pearls VC | Venture Capital | Minority | 000 0000 | 000000 0 |